EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSTNIG00000008104
Gene Symbol: CACNG8
2 Cross references
159 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSTNIG00000012624
Gene Symbol: CACNA1A
2 Cross references
176 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSTNIG00000005212
Gene Symbol: CACNA1B
2 Cross references
218 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSTNIG00000012020
Gene Symbol: CACNA1D
3 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSTNIG00000015498
Gene Symbol: CACNA1E
2 Cross references
214 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSTNIG00000005450
Gene Symbol: CACNA1H
2 Cross references
208 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSTNIG00000017296
Gene Symbol: CNR1
3 Cross references
134 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSTNIG00000016409
Gene Symbol: CNR1
2 Cross references
150 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSTNIG00000004059
Gene Symbol: CNR2
2 Cross references
191 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSTNIG00000008411
Gene Symbol: CA12
2 Cross references
214 Possible Orthologues:

Carbonic Anhydrase 6

Ensembl ID : ENSTNIG00000015155
Gene Symbol: CA6
2 Cross references
201 Possible Orthologues:

Carbonic Anhydrase Iv A

Ensembl ID : ENSTNIG00000008558
Gene Symbol: CA4A
2 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).